Sotatercept cuts risk of death and hospitalization by 76% in advanced pulmonary arterial hypertension

Published in The New England Journal of Medicine on May 28, the Zenith trial marks the first demonstration of a survival benefit for sotatercept in late-stage pulmonary arterial hypertension